University of Hertfordshire

From the same journal

By the same authors

Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (’Spice’) intake?

Research output: Contribution to journal › Article › peer-review

Standard

Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (’Spice’) intake? / Orsolini, Laura; Papanti, Duccio; Corkery, John; De Luca, Maria Antonietta; Cadoni, Cristina; Di Chiara, Gaetano; Schifano, Fabrizio.

In: CNS & Neurological Disorders - Drug Targets, Vol. 16, 13.04.2017.

Research output: Contribution to journal › Article › peer-review

Harvard

Orsolini, L, Papanti, D, Corkery, J, De Luca, MA, Cadoni, C, Di Chiara, G & Schifano, F 2017, 'Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (’Spice’) intake?', CNS & Neurological Disorders - Drug Targets, vol. 16. https://doi.org/10.2174/1871527316666170413101257

APA

Orsolini, L., Papanti, D., Corkery, J., De Luca, M. A., Cadoni, C., Di Chiara, G., & Schifano, F. (2017). Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (’Spice’) intake? CNS & Neurological Disorders - Drug Targets, 16. https://doi.org/10.2174/1871527316666170413101257

Vancouver

Orsolini L, Papanti D, Corkery J, De Luca MA, Cadoni C, Di Chiara G et al. Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (’Spice’) intake? CNS & Neurological Disorders - Drug Targets. 2017 Apr 13;16. https://doi.org/10.2174/1871527316666170413101257

Author

Orsolini, Laura ; Papanti, Duccio ; Corkery, John ; De Luca, Maria Antonietta ; Cadoni, Cristina ; Di Chiara, Gaetano ; Schifano, Fabrizio. / Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (’Spice’) intake?. In: CNS & Neurological Disorders - Drug Targets. 2017 ; Vol. 16.

Bibtex

@article{9e92a98366e641f88409c35c3f13dff3,
title = "Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics{\textquoteright} ({\textquoteright}Spice{\textquoteright}) intake?",
abstract = "Background: Substance use, including cannabis, has been documented amongst women both in the pre-conception period and during pregnancy, particularly during the 1st trimester, which is clearly the most critical period in the organogenesis. The recent emergence on the drug market of syntheticcannabimimetics/SC ({\textquoteleft}spice{\textquoteright}) may represent a new challenge for clinicians.Objective: A literature overview on the teratogenicity profile of both cannabis and synthetic cannabimimetics was here carried out.Methods: The PubMed database was searched in order to collect all relevant cases and data regarding the possible evidence of teratogenicity issues associated with cannabis and SC intake.Results: The use of cannabis in pregnant women has been associated with a plethora of both obstetrical/gestational complications and neurobehavioral/neurological effects on newborns. Conversely, onlyfew and conflicting data are related to SC misuse issues.Conclusion: Although cannabis use may be considered a risk factor for the occurrence of pregnancy related morbidity issues, many studies relied on self-reports and showed inconsistent results when controlling for potential confounders, including tobacco use. Given the role of the endocannabinoid system in both pregnancy and delivery, SC potency at interacting with the endocannabinoid system may be a reason of concern. Clinicians should carefully assess each woman planning a pregnancy, or who is pregnant already, and who is at risk of persisting in her current cannabis and/or SC intake. A nonjudgmental approach, aiming at collecting both a history of drug/alcohol use and at providing information regarding the risks associated with cannabis/SC intake during pregnancy is here advised.",
keywords = "Cannabis, pregnancy, synthetic cannabimimetics, synthetic cannabinoids, teratogenicity",
author = "Laura Orsolini and Duccio Papanti and John Corkery and {De Luca}, {Maria Antonietta} and Cristina Cadoni and {Di Chiara}, Gaetano and Fabrizio Schifano",
note = "Submitted: December 12, 2016 Revised: January 15, 2017 Accepted: March 10, 2017",
year = "2017",
month = apr,
day = "13",
doi = "10.2174/1871527316666170413101257",
language = "English",
volume = "16",
journal = "CNS & Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",

}

RIS

TY - JOUR

T1 - Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics’ (’Spice’) intake?

AU - Orsolini, Laura

AU - Papanti, Duccio

AU - Corkery, John

AU - De Luca, Maria Antonietta

AU - Cadoni, Cristina

AU - Di Chiara, Gaetano

AU - Schifano, Fabrizio

N1 - Submitted: December 12, 2016 Revised: January 15, 2017 Accepted: March 10, 2017

PY - 2017/4/13

Y1 - 2017/4/13

N2 - Background: Substance use, including cannabis, has been documented amongst women both in the pre-conception period and during pregnancy, particularly during the 1st trimester, which is clearly the most critical period in the organogenesis. The recent emergence on the drug market of syntheticcannabimimetics/SC (‘spice’) may represent a new challenge for clinicians.Objective: A literature overview on the teratogenicity profile of both cannabis and synthetic cannabimimetics was here carried out.Methods: The PubMed database was searched in order to collect all relevant cases and data regarding the possible evidence of teratogenicity issues associated with cannabis and SC intake.Results: The use of cannabis in pregnant women has been associated with a plethora of both obstetrical/gestational complications and neurobehavioral/neurological effects on newborns. Conversely, onlyfew and conflicting data are related to SC misuse issues.Conclusion: Although cannabis use may be considered a risk factor for the occurrence of pregnancy related morbidity issues, many studies relied on self-reports and showed inconsistent results when controlling for potential confounders, including tobacco use. Given the role of the endocannabinoid system in both pregnancy and delivery, SC potency at interacting with the endocannabinoid system may be a reason of concern. Clinicians should carefully assess each woman planning a pregnancy, or who is pregnant already, and who is at risk of persisting in her current cannabis and/or SC intake. A nonjudgmental approach, aiming at collecting both a history of drug/alcohol use and at providing information regarding the risks associated with cannabis/SC intake during pregnancy is here advised.

AB - Background: Substance use, including cannabis, has been documented amongst women both in the pre-conception period and during pregnancy, particularly during the 1st trimester, which is clearly the most critical period in the organogenesis. The recent emergence on the drug market of syntheticcannabimimetics/SC (‘spice’) may represent a new challenge for clinicians.Objective: A literature overview on the teratogenicity profile of both cannabis and synthetic cannabimimetics was here carried out.Methods: The PubMed database was searched in order to collect all relevant cases and data regarding the possible evidence of teratogenicity issues associated with cannabis and SC intake.Results: The use of cannabis in pregnant women has been associated with a plethora of both obstetrical/gestational complications and neurobehavioral/neurological effects on newborns. Conversely, onlyfew and conflicting data are related to SC misuse issues.Conclusion: Although cannabis use may be considered a risk factor for the occurrence of pregnancy related morbidity issues, many studies relied on self-reports and showed inconsistent results when controlling for potential confounders, including tobacco use. Given the role of the endocannabinoid system in both pregnancy and delivery, SC potency at interacting with the endocannabinoid system may be a reason of concern. Clinicians should carefully assess each woman planning a pregnancy, or who is pregnant already, and who is at risk of persisting in her current cannabis and/or SC intake. A nonjudgmental approach, aiming at collecting both a history of drug/alcohol use and at providing information regarding the risks associated with cannabis/SC intake during pregnancy is here advised.

KW - Cannabis

KW - pregnancy

KW - synthetic cannabimimetics

KW - synthetic cannabinoids

KW - teratogenicity

UR - https://www.ncbi.nlm.nih.gov/pubmed/28412917

U2 - 10.2174/1871527316666170413101257

DO - 10.2174/1871527316666170413101257

M3 - Article

VL - 16

JO - CNS & Neurological Disorders - Drug Targets

JF - CNS & Neurological Disorders - Drug Targets

SN - 1871-5273

ER -